- Investing.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Market Valuation | Delve into Insulet's high valuation multiples, with analyst price targets ranging from $266 to $365, reflecting strong growth prospects in medical technology |
Leadership Transition | New CEO Ashley McEvoy's appointment signals potential for accelerated growth and market expansion, despite initial investor uncertainty |
Growth Trajectory | Explore Insulet's robust Q1 2025 performance, revised revenue guidance, and strategic expansion into Type 2 diabetes market, driving substantial growth |
Patch Pump Pionee | Insulet leads the diabetes management market with innovative patch pump technology, boasting impressive financial health and a "GREAT" rating from InvestingPro |

Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 56.8x | 11.7x | −0.5x | |
PEG Ratio | −1.42 | 0.03 | 0.00 | |
Price / Book | 9.3x | 8.1x | 2.6x | |
Price / LTM Sales | 5.2x | 4.7x | 3.2x | |
Upside (Analyst Target) | 75.9% | 30.5% | 47.6% | |
Fair Value Upside | Unlock | 3.1% | 6.1% | Unlock |